Author:
Diao Sheng-Peng,Zhuang Yang-Sha,Huang Ye-Qing,Zhou Zhi-Hua,Liu Ai-Qun,Hong Ming-Fan
Abstract
Abstract
Objective
To analyze and explore the risk factors for neurological symptoms in patients with purely hepatic Wilson's disease (WD) at diagnosis.
Methods
This retrospective study was conducted at the First Affiliated Hospital of the Guangdong Pharmaceutical University on 68 patients with purely hepatic WD aged 20.6 ± 7.2 years. The physical examinations, laboratory tests, color Doppler ultrasound of the liver and spleen, and magnetic resonance imaging (MRI) of the brain were performed.
Results
The elevated alanine transaminase (ALT) and aspartate transaminase (AST) levels and 24-h urinary copper level were higher in the purely hepatic WD who developed neurological symptoms (NH-WD) group than those in the purely hepatic WD (H-WD) group. Adherence to low-copper diet, and daily oral doses of penicillamine (PCA) and zinc gluconate (ZG) were lower in the NH-WD group than those in the H-WD group. Logistic regression analysis showed that insufficient doses of PCA and ZG were associated with the development of neurological symptoms in patients with purely hepatic WD at diagnosis.
Conclusion
The development of neurological symptoms in patients with purely hepatic WD was closely associated with insufficient doses of PCA and ZG, and the inferior efficacy of copper-chelating agents. During the course of anti-copper treatment, the patient's medical status and the efficacy of copper excretion should be closely monitored.
Funder
Medical Scientific Research Foundation of the Guangdong Province
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),General Medicine
Reference31 articles.
1. Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol. 2015;14(1):103–13.
2. Lo C, Bandmann O. Epidemiology and introduction to the clinical presentation of Wilson disease. Handb Clin Neurol. 2017;142:7–17.
3. Chen C, Shen B, Xiao JJ, et al. Currently clinical views on genetics of Wilson’s disease. Chin Med J. 2015;128(13):1826–30.
4. Ala A, Walker AP, Ashkan K, et al. Wilson’s disease. Lancet. 2007;369(9559):397–408.
5. Group of Neurogenetics, Society of Neurology, Chinese Medical Association Chinese guidelines for diagnosis and treatment of hepatolenticular degeneration 2021. Chin J Neurol. 2021;54(4):310–9.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献